Gimeracil sensitizes cells to radiation via inhibition of homologous recombination

Radiotherapy and Oncology

Volumn 96, Issue 2, 2010, Pages 259-266

  Takagi, Masaru ^a   Sakata, Koh Ichi ^a   Someya, Masanori ^a   Tauchi, Hiroshi ^b   Iijima, Kenta ^b   Matsumoto, Yoshihisa ^c   Torigoe, Toshihiko ^d   Takahashi, Akari ^d   Hareyama, Masato ^d   Fukushima, Masakazu ^e  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b IBARAKI UNIVERSITY   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

^e TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

DNA double strand breaks; Gimeracil; Homologous recombination; Radiosensitizer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DNA; GAMMA HISTONE H2AX; GIMERACIL; NUCLEAR PROTEIN; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER RADIOTHERAPY; CELL CLONE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CLONOGENIC ASSAY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFECT; FEMALE; HELA CELL; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; LUNG FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; RADIOFREQUENCY; RADIOSENSITIZATION;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; PYRIDINES; RADIATION TOLERANCE; RECOMBINATION, GENETIC;

EID: 77955717821     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.05.020     Document Type: Article

References (31)

1. E.J. Hall Radiosensitizers and bioreductive drugs E.J. Hall, A.M. Giaccia, Radiobiology for the radiologist 6th ed. 2006 Lippincott Williams & Wilkins Philadelphia 419 431
2. K. Tatsumi, M. Fukushima, and T. Shirasaka Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 1987 748 755
3. T. Shirasaka, Y. Shimamato, and H. Ohshimo Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 1996 548 557
4. W. Koizumi, H. Narahara, and T. Hara S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 2008 215 221
5. S. Sakuramoto, M. Sasako, and T. Yamaguchi Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 2007 1810 1820
6. J. Van den Brande, P. Schoffski, and J.H. Schellens EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer Br J Cancer 88 2003 648 653
7. K. Harada, M. Sato, and Y. Ueyama Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma Anticancer Drugs 19 2008 85 90
8. M. Kawahara, K. Furuse, and Y. Segawa Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer Br J Cancer 85 2001 939 943
9. H. Shinchi, K. Maemura, and H. Noma Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer Br J Cancer 96 2007 1353 1357
10. M. Tahara Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC) Jpn J Cancer Chemother 33 2006 167 171
11. H. Tauchi, J. Kobayashi, and K. Morishima The forkhead-associated domain of NBS1 is essential for nuclear foci formation after irradiation but not essential for hRAD50[middle dot]hMRE11[middle dot]NBS1 complex DNA repair activity J Biol Chem 276 2001 12 15
12. A. Errami, V. Smider, and W.K. Rathmell Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants Mol Cell Biol 16 1996 1519 1526
13. V. Smider, W.K. Rathmell, and M.R. Lieber Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA Science 266 1994 288 291
14. B.K. Singleton, A. Priestley, and H. Steingrimsdottir Molecular and biochemical characterization of xrs mutants defective in Ku80 Mol Cell Biol 17 1997 1264 1273
15. G.E. Taccioli, T.M. Gottlieb, and T. Blunt Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination Science 265 1994 1442 1445
16. J.M. Buerstedde, and S. Takeda Increased ratio of targeted to random integration after transfection of chicken B cell lines Cell 67 1991 179 188
17. M. Someya, K. Sakata, and Y. Matsumoto The association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer Carcinogenesis 27 2006 117 122
18. H. Tauchi, J. Kobayashi, and K. Morishima Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells Nature 420 2002 93 98
19. S. Sakamoto, K. Iijima, and D. Mochizuki Homologous recombination repair is regulated by domains at the N- and C-terminus of NBS1 and is dissociated with ATM functions Oncogene 26 2007 6002 6009
20. E.J. Hall Cell, tissue, and tumor kinetics E.J. Hall, A.M. Giaccia, Radiobiology for the radiologist 6th ed. 2006 Lippincott Williams & Wilkins Philadelphia 16 29
21. T. Helleday, J. Lo, and D.C. van Gent DNA double-strand break repair: from mechanistic understanding to cancer treatment DNA Repair 6 2007 923 935
22. E.J. Hall Repair of radiation damage and the dose-rate effect E.J. Hall, A.M. Giaccia, Radiobiology for the radiologist 6th ed. 2006 Lippincott Williams & Wilkins Philadelphia 60 84
23. J. Dziegiewski, W. Goetz, and J.S. Murley Amifostine metabolite WR-1065 disrupts homologous recombination in mammalian cells Radiat Res 173 2010 175 183
24. Y. Murakawa, E. Sonoda, and L.J. Barber Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells Cancer Res 67 2007 8536 8543
25. L. Li, H. Wang, and E.S. Yang Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells Cancer Res 68 2008 9141 9146
26. A. Choudhury, H. Zhao, and F. Jalali Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity Mol Cancer Ther 8 2009 203 213
27. K. Hirata, N. Horikoshi, and K. Aiba Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug Clin Cancer Res 5 1999 2000 2005
28. T. Hayashi, G. Tanaka, and K. Irimura Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo J Toxicol Sci 21 1996 495 504
29. A. Ohuchida, Y. Kouchi, and S. Sato Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo J Toxicol Sci 21 1996 675 689
30. H. Utsumi, and M.M. Elkind Requirement for repair of DNA double-strand breaks by homologous recombination in split-dose recovery Radiat Res 155 2001 680 686
31. H. Willers, J. Dahm-Daphi, and S.N. Powell Repair of radiation damage to DNA Br J Cancer 90 2004 1297 1301